280 related articles for article (PubMed ID: 22149371)
1. Istradefylline for the treatment of Parkinson's disease.
Park A; Stacy M
Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
[TBL] [Abstract][Full Text] [Related]
2. The safety of istradefylline for the treatment of Parkinson's disease.
Müller T
Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
[TBL] [Abstract][Full Text] [Related]
3. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
[TBL] [Abstract][Full Text] [Related]
4. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
5. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Jenner P
Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
7. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
8. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
9. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Müller T
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
[TBL] [Abstract][Full Text] [Related]
10. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
11. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
[TBL] [Abstract][Full Text] [Related]
12. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
[TBL] [Abstract][Full Text] [Related]
14. The effect of istradefylline for Parkinson's disease: A meta-analysis.
Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
[TBL] [Abstract][Full Text] [Related]
15. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
[TBL] [Abstract][Full Text] [Related]
16. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
17. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
Perez-Lloret S; Merello M
Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
[TBL] [Abstract][Full Text] [Related]
18. Istradefylline (Nourianz) for Parkinson's disease.
Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
[No Abstract] [Full Text] [Related]
19. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.
Fernandez HH; Greeley DR; Zweig RM; Wojcieszek J; Mori A; Sussman NM;
Parkinsonism Relat Disord; 2010 Jan; 16(1):16-20. PubMed ID: 19616987
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Hauser RA; Hubble JP; Truong DD;
Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]